BioMedLib Search Engine [ goto HOMEPAGE ]

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] B-cell non-Hodgkin lymphoma presenting as an endobronchial polypoid mass.

[MeSH-major] Bronchial Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis

[MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Doxorubicin / therapeutic use. Humans. Male. Middle Aged. Prednisone / therapeutic use. Vincristine / therapeutic use

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18449008.001).

[ISSN] 1556-1380

[Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

[ISO-abbreviation] J Thorac Oncol

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] If it is in the marrow, is it also in the blood? An analysis of 1,000 paired samples from patients with B-cell non-Hodgkin lymphoma.

BACKGROUND: Staging of B-cell non Hodgkin's lymphoma (NHL) routinely involves bone marrow (BM) examination by trephine biopsy (BM-TB).

The evidence of disease in the BM-TB results in a clinical stage IV classification affecting therapeutic strategies for NHL patients.

BM immunophenotyping by flow cytometry (FC) is also used, although its clinical value is still under debate.

Aberrant immunophenotypes present in the B-cell subpopulation were also investigated.

Concordance was defined as the presence of a positive (in terms of disease detection) or negative result in both BM-FC and PB-FC or BM-TB and BM-FC.

Among the discordant cases (ie presence of neoplastic B-lymphocyte in the BM but under the sensibility of the technique in the PB) the most frequent diagnosis was Waldenstrom's macroglobulinemia (WM, accounting for 20.8% of all discordant cases).

The expression of CXCR4, a receptor involved in B-cell trafficking and homing, was found to be down regulated in WM compared to other NHL types, thus suggesting a possible role of CXCR4 in WM cell homing in the BM.

CONCLUSIONS: The finding that FC data from BM and PB samples overlap in NHL might have major implications for the design of future clinical studies and for patients' follow-up.

[MeSH-major] Bone Marrow / pathology. Lymphoma, B-Cell / blood. Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / blood. Lymphoma, Non-Hodgkin / diagnosis

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Blood. 1999 Dec 1;94(11):3889-96 [10572105.001]

[Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]

[Cites] Cancer Res. 2002 Jun 1;62(11):3106-12 [12036921.001]

[Cites] Leukemia. 2002 Aug;16(8):1460-9 [12145686.001]

[Cites] Histopathology. 2004 Sep;45(3):268-74 [15330805.001]

[Cites] J Clin Oncol. 1995 Jun;13(6):1336-42 [7751877.001]

[Cites] Br J Haematol. 2006 Feb;132(3):255-67 [16409290.001]

[Cites] J Clin Oncol. 2007 Feb 10;25(5):579-86 [17242396.001]

[Cites] Eur J Clin Invest. 2007 Apr;37(4):305-9 [17373966.001]

[Cites] Leukemia. 2007 May;21(5):956-64 [17361231.001]

[Cites] Blood. 2008 Jul 1;112(1):150-8 [18448868.001]

(PMID = 21106070.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / CXCR4 protein, human; 0 / Receptors, CXCR4

[Other-IDs] NLM/ PMC2995803

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.

Most non-Hodgkin lymphomas (NHLs) are of B-cell origin, but the tumor tissue can be variably infiltrated with T cells.

In the present study, we have identified a subset of CD4(+)CD25(+) T cells with high levels of CTLA-4 and Foxp3 (intratumoral T(reg) cells) that are overrepresented in biopsy specimens of B-cell NHL (median of 17% in lymphoma biopsies, 12% in inflammatory tonsil, and 6% in tumor-free lymph nodes; P = .001).

We found that these CD4(+)CD25(+) T cells suppressed the proliferation and cytokine (IFN-gamma and IL-4) production of infiltrating CD4(+)CD25(-) T cells in response to PHA stimulation.

PD-1 was found to be constitutively and exclusively expressed on a subset of infiltrating CD4(+)CD25(-) T cells, and B7-H1 could be induced on intratumoral CD4(+)CD25(+) T cells in B-cell NHL.

Anti-B7-H1 antibody or PD-1 fusion protein partly restored the proliferation of infiltrating CD4(+)CD25(-) T cells when cocultured with intratumoral T(reg) cells.

Finally, we found that CCL22 secreted by lymphoma B cells is involved in the chemotaxis and migration of intratumoral T(reg) cells that express CCR4, but not CCR8.

Taken together, our results suggest that T(reg) cells are highly represented in the area of B-cell NHL and that malignant B cells are involved in the recruitment of these cells into the area of lymphoma.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Immunol. 1999 May 1;162(9):5317-26 [10228007.001]

[Cites] J Immunol. 2004 Jan 15;172(2):834-42 [14707053.001]

[Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]

[Cites] Clin Cancer Res. 2005 Feb 15;11(4):1467-73 [15746048.001]

[Cites] Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85 [16001955.001]

[Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]

[Cites] J Immunol. 2005 Oct 1;175(7):4180-3 [16177055.001]

[Cites] J Exp Med. 2001 Sep 17;194(6):847-53 [11560999.001]

[Cites] Immunol Rev. 2001 Aug;182:18-32 [11722621.001]

[Cites] Nat Immunol. 2001 Dec;2(12):1126-32 [11702067.001]

[Cites] Cancer Res. 2001 Dec 15;61(24):8643-6 [11751377.001]

[Cites] J Immunol. 2002 May 1;168(9):4272-6 [11970966.001]

[Cites] Nat Rev Immunol. 2002 Jun;2(6):389-400 [12093005.001]

[Cites] J Exp Med. 2002 Jul 15;196(2):237-46 [12119348.001]

[Cites] Adv Immunol. 2003;81:331-71 [14711059.001]

[Cites] Blood. 2004 Mar 1;103(5):1755-62 [14604957.001]

[Cites] Semin Immunol. 2004 Apr;16(2):81-8 [15036231.001]

[Cites] Semin Immunol. 2004 Apr;16(2):89-98 [15036232.001]

[Cites] J Immunol. 2004 Jul 15;173(2):1444-53 [15240741.001]

[Cites] Nat Med. 2004 Sep;10(9):942-9 [15322536.001]

[Cites] J Immunol. 1995 Aug 1;155(3):1151-64 [7636184.001]

[Cites] Int Immunol. 1998 Dec;10(12):1969-80 [9885918.001]

[Cites] J Immunol. 1999 Nov 15;163(10):5211-8 [10553041.001]

[Cites] J Exp Med. 2000 Jul 17;192(2):295-302 [10899916.001]

[Cites] J Exp Med. 2000 Jul 17;192(2):303-10 [10899917.001]

[Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]

[Cites] Cancer Res. 2001 Jun 15;61(12):4766-72 [11406550.001]

[Cites] Nat Immunol. 2001 Sep;2(9):816-22 [11526392.001]

[Cites] J Exp Med. 2001 Sep 3;194(5):629-44 [11535631.001]

[Cites] J Exp Med. 2001 Sep 17;194(6):823-32 [11560997.001]

[Cites] J Exp Med. 2002 Jul 15;196(2):247-53 [12119349.001]

[Cites] J Exp Med. 2002 Jul 15;196(2):255-60 [12119350.001]

[Cites] J Exp Med. 2002 Aug 5;196(3):379-87 [12163566.001]

[Cites] J Immunol. 2002 Sep 1;169(5):2756-61 [12193750.001]

[Cites] Curr Opin Immunol. 2002 Dec;14(6):771-8 [12413528.001]

[Cites] J Allergy Clin Immunol. 2002 Nov;110(5):693-702 [12417876.001]

[Cites] J Exp Med. 2002 Nov 18;196(10):1335-46 [12438424.001]

[Cites] J Immunol. 2002 Dec 1;169(11):6210-7 [12444126.001]

[Cites] J Clin Invest. 2003 Feb;111(3):363-70 [12569162.001]

[Cites] Science. 2003 Feb 14;299(5609):1057-61 [12522256.001]

[Cites] Nat Immunol. 2003 Apr;4(4):330-6 [12612578.001]

[Cites] Nat Immunol. 2003 Apr;4(4):337-42 [12612581.001]

[Cites] Cancer. 2003 Sep 1;98(5):1089-99 [12942579.001]

[Cites] Clin Cancer Res. 2003 Oct 1;9(12):4404-8 [14555512.001]

[Cites] Curr Opin Immunol. 2003 Dec;15(6):690-6 [14630204.001]

[Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]

(PMID = 16403912.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA92104; United States / NCI NIH HHS / CA / CA97274

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Antigens, Surface; 0 / Apoptosis Regulatory Proteins; 0 / CD274 protein, human; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor; 0 / Receptors, Interleukin-2; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma

[Other-IDs] NLM/ PMC1895773

   

Advertisement

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients.

A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as "non-resected" stage II/I and CNS-negative advanced-stage IIV/IV (70% of cases).

There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell).

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / drug therapy

[MeSH-minor] Adolescent. Adult. Burkitt Lymphoma / drug therapy. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Remission Induction. Risk Factors. Survival Rate. Time Factors. Vincristine / administration & dosage

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Am J Pediatr Hematol Oncol. 1991 Fall;13(3):288-95 [1793154.001]

[Cites] Blood. 2006 May 15;107(10):4047-52 [16424389.001]

[Cites] J Clin Oncol. 1996 Mar;14(3):925-34 [8622041.001]

[Cites] Blood. 1999 Nov 15;94(10):3294-306 [10552938.001]

[Cites] Br J Cancer. 2000 Apr;82(8):1396-402 [10780517.001]

[Cites] J Clin Oncol. 2001 Jan 15;19(2):414-9 [11208833.001]

[Cites] Blood. 2001 Jun 1;97(11):3370-9 [11369626.001]

[Cites] J Clin Oncol. 2002 Jan 15;20(2):441-8 [11786572.001]

[Cites] Leukemia. 2002 Apr;16(4):594-600 [11960338.001]

[Cites] J Clin Oncol. 2002 Jun 15;20(12):2783-8 [12065554.001]

[Cites] Br J Haematol. 2003 Feb;120(4):660-70 [12588354.001]

[Cites] Cancer. 2004 Jul 15;101(2):385-94 [15241838.001]

[Cites] J Pediatr Hematol Oncol. 2004 Sep;26(9):555-60 [15342981.001]

[Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]

[Cites] J Chronic Dis. 1981;34(9-10):469-79 [7276137.001]

[Cites] J Chronic Dis. 1985;38(8):683-90 [4019705.001]

[Cites] J Clin Oncol. 1986 Aug;4(8):1219-26 [3525767.001]

[Cites] J Clin Oncol. 1989 Mar;7(3):304-9 [2493074.001]

[Cites] Stat Med. 1989 Oct;8(10):1191-8 [2814068.001]

[Cites] J Clin Oncol. 1991 Jan;9(1):123-32 [1985161.001]

[Cites] J Clin Oncol. 1996 Apr;14(4):1252-61 [8648381.001]

[Cites] Med Pediatr Oncol. 1997 Dec;29(6):526-33 [9324339.001]

[Cites] Br J Cancer. 1998 Jun;77(12):2281-5 [9649146.001]

[Cites] Blood. 2005 Feb 1;105(3):948-58 [15486066.001]

[Cites] J Clin Oncol. 1995 Feb;13(2):359-72 [7844597.001]

(PMID = 17132719.001).

[ISSN] 0006-4971

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MEVAP protocol

[Other-IDs] NLM/ PMC1852229

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma.

In T- and pre-B-cell lymphoma, KLF4 was found to act as tumor suppressor.

We found the KLF4 promoter methylated in B-cell lymphoma cell lines and in primary cases of B-cell lymphomas, namely, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, and in classic Hodgkin lymphoma (cHL) cases.

Conditional overexpression of KLF4 in Burkitt lymphoma cell lines moderately retarded proliferation, via cell-cycle arrest in G(0)/G(1).

In the cHL cell lines, KLF4 induced massive cell death that could partially be inhibited with Z-VAD.fmk.

These genes are specifically up-regulated in HRS cells of cHL and known to be involved in establishing the cHL phenotype.

We conclude that epigenetic silencing of KLF4 in B-cell lymphomas and particularly in cHL may favor lymphoma survival by loosening cell-cycle control and protecting from apoptosis.

[MeSH-major] Burkitt Lymphoma / metabolism. Genes, Tumor Suppressor. Hodgkin Disease / metabolism. Kruppel-Like Transcription Factors / physiology. Lymphoma, Follicular / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism

[MeSH-minor] Apoptosis. B-Lymphocytes / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Proliferation. Child. Child, Preschool. DNA Methylation. DNA, Neoplasm / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Humans. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. bcl-2 Homologous Antagonist-Killer Protein / antagonists & inhibitors. bcl-2 Homologous Antagonist-Killer Protein / genetics. bcl-2 Homologous Antagonist-Killer Protein / metabolism

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - Hodgkin Disease.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20519630.001).

[ISSN] 1528-0020

[Journal-full-title] Blood

[ISO-abbreviation] Blood

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / BAK1 protein, human; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / RNA, Messenger; 0 / bcl-2 Homologous Antagonist-Killer Protein

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Palifermin, a recombinant human keratinocyte growth factor, triggers reactivation of anogenital human papillomavirus infection in a HIV-positive patient with diffuse large cell B-cell non-Hodgkin lymphoma.

[MeSH-major] Alphapapillomavirus. Condylomata Acuminata. Fibroblast Growth Factor 7 / adverse effects. HIV Seropositivity. Lymphoma, Large B-Cell, Diffuse

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - Lymphoma, large-cell.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Genital Warts.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19421177.001).

[ISSN] 1476-5365

[Journal-full-title] Bone marrow transplantation

[ISO-abbreviation] Bone Marrow Transplant.

[Language] eng

[Publication-type] Case Reports; Letter

[Publication-country] England

[Chemical-registry-number] 126469-10-1 / Fibroblast Growth Factor 7

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Transcriptional inactivation of p53, Bax, Bcl-2 and Mdm2 correlates with malignant transformation of the uterine cervix.

Deregulation of the apoptotic machinery plays a major role in cell death, cellular transformation and cancer. p53, Bcl-2, Bcl-XL, Bax and Mdm2 mRNA expression patterns were evaluated in tissue samples with cervical intraepithelial neoplasia (CIN) and cervical cancer compared to those of normal cervical tissues, and correlated with the underlying cervical lesions.

Transcript levels of the above genes were assessed by RT-PCR analysis in a total of 44 cervical specimens. p53, Bcl-2, Bax and Mdm2 transcript levels were significantly different in the normal, CIN and cancer specimen groups (p=0.003, p=0.009, p=0.040 and p=0.001, respectively).

Specifically, p53, Bax and Bcl-2 exhibited substantially lower transcript levels in CIN lesions compared to controls, whereas Bax mRNA levels showed a significant decrease in cancer compared to normal specimens.

High-grade squamous intraepithelial lesions exhibited lower p53 and Bcl-2 mRNA levels than controls (p=0.002, p=0.016).

Coexpression analysis revealed more correlations between the above apoptosis-related molecules in normal tissues compared to CIN or cancer specimens. p53 showed significant coexpression with Bax, Bcl-2 and Mdm2 (p=0.040, p=0.013 and p=0.015, respectively) in normal cervical specimens.

Bax and Bcl-XL mRNA expression was negatively correlated.

Mdm2 transcriptional levels correlated significantly with those of Bax, Bcl-XL and Bcl-2.

Our findings show that p53, Bax, Bcl-2 and Mdm2 mRNA expression levels correlate with the malignant transformation of the uterine cervix. mRNA coexpression patterns of the members of the pro- and anti-apoptotic family examined in cervical carcinogenesis were found to be disrupted in CIN and cancer, as already demonstrated at the protein level. (Int J Biol Markers 2005; 20: 18-27).

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28207100.001).

[ISSN] 1724-6008

[Journal-full-title] The International journal of biological markers

[ISO-abbreviation] Int. J. Biol. Markers

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Novel agents for B-cell non-Hodgkin lymphoma: science and the promise.

New molecular targets in neoplastic cells are emerging and provide the rationale for clinical development of novel agents in non-Hodgkin lymphoma.

The purpose of this review is to focus on these novel agents and the various treatment approaches that are currently being evaluated in non-Hodgkin lymphoma.

[MeSH-major] Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Copyright] Published by Elsevier Ltd.

(PMID = 20153097.001).

[ISSN] 1532-1681

[Journal-full-title] Blood reviews

[ISO-abbreviation] Blood Rev.

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] England

[Chemical-registry-number] 0 / Antineoplastic Agents

[Number-of-references] 143

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Extranodal primary B-cell non-Hodgkin lymphoma of the breast mimicking acute mastitis.

We report a case of primary, high-grade non-Hodgkin B-cell lymphoma in the breast of a young woman.

The clinical and sonographic presentation was not of a mass but of an infiltrating anechoic process mimicking mastitis.

Primary breast lymphoma is a rare entity, especially in young females.

In previous imaging reports of breast lymphoma, it has always been considered as a mass, though the presence of markedly hypoechoic regions that look like fluid collections is a well known sonographic characteristic of lymphoma.

[MeSH-major] Breast Neoplasms / ultrasonography. Lymphoma, B-Cell / ultrasonography. Mastitis / diagnosis

[MeSH-minor] Acute Disease. Adult. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Positron-Emission Tomography. Tomography, X-Ray Computed. Ultrasonography, Mammary

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15756660.001).

[ISSN] 0091-2751

[Journal-full-title] Journal of clinical ultrasound : JCU

[ISO-abbreviation] J Clin Ultrasound

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intrachromosomal rearrangement of chromosome 3q27: an under recognized mechanism of BCL6 translocation in B-cell non-Hodgkin lymphoma.

Balanced reciprocal translocations involving chromosomal region 3q27, which led to identification of the BCL6 protooncogene, are one of the most common recurrent chromosomal abnormalities reported in B-cell non-Hodgkin lymphomas (B-NHL).

Cloning of the breakpoints of these translocations has facilitated the identification of a number of BCL6 partners including immunoglobulin genes and more than 20 non-immunoglobulin genes on almost all human chromosomes.

These rearrangements accounted for 3/20 (15%) of all BCL6 translocations occurring in B-NHL, including follicular lymphomas, diffuse large B-cell lymphomas, and marginal zone B-cell lymphomas, diagnosed at our institute.

Our data should help facilitate the identification of new BCL6 partner genes, which may enhance our understanding of the clinical and biological role of BCL6 in B-NHL pathogenesis.

[MeSH-major] Chromosomes, Human, Pair 3. DNA-Binding Proteins / genetics. Gene Rearrangement. Lymphoma, B-Cell / genetics. Translocation, Genetic / genetics

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16867873.001).

[ISSN] 0046-8177

[Journal-full-title] Human pathology

[ISO-abbreviation] Hum. Pathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / BCL6 protein, human; 0 / DNA-Binding Proteins

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells.

Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies.

The goal of these newer agents is to achieve similar or better response rates as seen with rituximab, and perhaps demonstrate activity in rituximab-refractory disease.

Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.

[MeSH-major] Antibodies, Monoclonal / chemistry. Immunotherapy / methods. Lymphoma, B-Cell / therapy

[MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / chemistry. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Epitopes / chemistry. Humans. Medical Oncology / methods. Rituximab. Treatment Outcome

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]

[Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]

[Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]

[Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]

[Cites] Ann Oncol. 2007 Jul;18(7):1216-23 [17470451.001]

[Cites] Clin Cancer Res. 2006 Jan 1;12(1):242-9 [16397048.001]

[Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]

[Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]

[Cites] Clin Cancer Res. 2004 Apr 15;10(8):2868-78 [15102696.001]

[Cites] Semin Immunol. 1998 Aug;10(4):287-97 [9695185.001]

[Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]

[Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]

[Cites] Cancer Res. 2005 Sep 15;65(18):8331-8 [16166310.001]

[Cites] Blood. 1984 Nov;64(5):1085-93 [6333257.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1926-30 [12571354.001]

[Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]

[Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]

[Cites] J Biol Chem. 2001 Mar 2;276(9):6591-604 [11096108.001]

[Cites] N Engl J Med. 1982 Mar 4;306(9):517-22 [6173751.001]

[Cites] Arthritis Res Ther. 2006;8(3):R74 [16630358.001]

[Cites] Drugs. 2007;67(3):333-50 [17335294.001]

[Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]

[Cites] Clin Cancer Res. 2004 Aug 15;10(16):5297-8 [15328164.001]

[Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]

[Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]

[Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]

[Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]

[Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]

[Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]

[Cites] J Immunol. 2000 Apr 15;164(8):4178-84 [10754313.001]

[Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3995S-4002S [14506199.001]

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]

(PMID = 18706270.001).

[ISSN] 1534-6269

[Journal-full-title] Current oncology reports

[ISO-abbreviation] Curr Oncol Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Epitopes; 4F4X42SYQ6 / Rituximab

[Number-of-references] 37

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Functional signatures identified in B-cell non-Hodgkin lymphoma profiles.

Gene-expression profiling in B-cell lymphomas has provided crucial data on specific lymphoma types, which can contribute to the identification of essential lymphoma survival genes and pathways.

In this study, the gene-expression profiling data of all major B-cell lymphoma types were analyzed by unsupervised clustering.

The transcriptome classification so obtained, was explored using gene set enrichment analysis generating a heatmap for B-cell lymphoma that identifies common lymphoma survival mechanisms and potential therapeutic targets, recognizing sets of coregulated genes and functional pathways expressed in different lymphoma types.

Some of the most relevant signatures (stroma, cell cycle, B-cell receptor (BCR)) are shared by multiple lymphoma types or subclasses.

A specific attention was paid to the analysis of BCR and coregulated pathways, defining molecular heterogeneity within multiple B-cell lymphoma types.

[MeSH-major] Gene Expression Profiling. Lymphoma, B-Cell / genetics. Neoplasm Proteins / genetics. RNA, Messenger / genetics. RNA, Neoplasm / genetics

Genetic Alliance. consumer health - Hodgkin lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19863341.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Nuclear morphometry and texture analysis of B-cell non-Hodgkin lymphoma: utility in subclassification on cytosmears.

Non-Hodgkin lymphoma (NHL) is a heterogeneous group of lymphoid neoplasms and accurate subclassification is an essential prerequisite for proper management of patients.

Fine needle aspiration smears of 50 cases of B-cell NHL were included.

The percentage of cells correctly classified to a particular NHL subtype using the discriminant functions so obtained was noted.Our results show that discriminant analysis done on size parameters could correctly classify a greater number of cells than on shape parameters (36.4% vs. 21.2%, respectively).

Texture parameters based on single pixel values (first order texture) were inferior (42.8%) to those based on pair of pixels (58.7%) in subtyping of cells.

Using all the morphometric and textural parameters together, 83.3% of cells could be correctly classified to a particular NHL subtype.The present study, perhaps the first study of detailed morphometric analysis on cytosmears, shows that satisfactory classification of NHL on aspiration cytology is possible using nuclear morphometry and textural parameters considered together.

[MeSH-major] Cell Nucleus / ultrastructure. Cytodiagnosis / methods. Lymphoma, B-Cell / classification. Lymphoma, B-Cell / ultrastructure

Genetic Alliance. consumer health - Hodgkin lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19688760.001).

[ISSN] 1097-0339

[Journal-full-title] Diagnostic cytopathology

[ISO-abbreviation] Diagn. Cytopathol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antigens, CD

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Radioimmunotherapy for indolent B-cell non-Hodgkin lymphoma in relapsed, refractory and transformed disease.

In RIT, a radionuclide is coupled to a monoclonal antibody, directed against an antigen expressed on tumor cells.

Recently, RIT has been introduced targeting the CD20 surface antigen, which is expressed on nearly all B-cell non-Hodgkin lymphomas (NHL).

Clinical experience with RIT in the treatment of patients with indolent NHL is increasing.

In general, there is no organ-specific non-hematologic toxicity when a standard dose of RIT is used.

RIT is feasible in heavily pretreated patients and does not compromise future treatments in the event of progressive disease.

Randomized phase III studies are in progress to evaluate the timing of RIT in the overall management of indolent NHLInvestigations of new emerging therapeutic strategies for patients with indolent NHL are underway, with research into the feasibility of RIT as first-line therapy and in advanced disease, RIT dose escalation and combined modality approaches with autologous stem cell transplantation.

[MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy. Radioimmunotherapy / methods

[MeSH-minor] Disease Progression. Feasibility Studies. Humans. Models, Biological. Recurrence. Treatment Outcome

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Indolent B cell lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16831019.001).

[ISSN] 1173-8804

[Journal-full-title] BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

[ISO-abbreviation] BioDrugs

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] New Zealand

[Number-of-references] 42

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 5145 Background: Antiapoptotic Bcl-2 family proteins are overexpressed in castrate resistant prostate cancer (CRPC) and contribute to resistance to therapy.

AT-101 is a pan-Bcl-2 inhibitor (Bcl-2, Bcl-X_L, Bcl-W, and Mcl-1) and potent inducer of proapoptotic proteins.

Patients (pts) must have PSA progression per the Bubley criteria or documented disease progression while receiving prior D/P therapy.

Radiological assessments were performed at 6-wk intervals for pts with soft tissue disease and bone scans were performed after cycle 6 and at the completion of therapy.

Twenty one of 34 pts included in this analysis had measurable disease.

Five pts (24%) with measurable disease had a PR or CR by RECIST criteria and one additional patient had tumor shrinkage of 29%.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964445.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

: 8574 Background: ABT-263, a novel, orally bioavailable, BH3 mimetic, binds with high affinity (K_i ≤ 1nM) and inhibits multiple antiapoptotic Bcl-2 family proteins.

ABT-263 displays activity (EC₅₀ ≤ 1μM) against human lymphoid and small cell lung cancer cell lines.

Mechanism based preclinical toxicities include reductions in circulating lymphocytes, apoptosis of circulating platelets, and decreased spermatogenesis, mediated by inhibition of Bcl-2, Bcl-X_L, and Bcl-w, respectively.

6 pts maintained a ≥50% decrease in circulating lymphocytes for ≥ 2 months and 11 pts have stable disease; of these 5 experienced minor radiographic responses (range of 36% to 49%).

In addition, among 40 (M06-814) lymphoma pts, 3 with follicular lymphoma achieved PR and one had a minor response (49% regression).

Pharmacodynamic toxicities included dose-dependent thrombocytopenia (TCP) resulting from on-target activity against Bcl-X_L.

CONCLUSIONS: ABT-263 showed favorable PK and safety profiles with anti-tumor activity in relapsed/refractory CLL/SLL and follicular lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962273.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Expression of programmed death ligand 1 (PD-L1) by non-Hodgkin's lymphomas (NHL) and effect on tumor-associated T cells.

: 8526 Background: PD-L1 is expressed on antigen presenting cells and inhibits activation of T cells through its receptor, PD-1.

METHODS: PD-L1 expression was analyzed in 16 NHL cell lines by flow cytometry (FC) and in 111 lymphoma specimens by immunohistochemistry (IHC) (n=92) or FC (n=19).

In functional studies, irradiated anaplastic large cell lymphoma (ALCL) cells were co-cultured with allogeneic T cells in the presence of anti-PD-L1 blocking antibody, and IFNγ secretion and thymidine incorporation was used to assess T cell function and proliferation.

To further test tumor-T cell interactions, malignant ascites from a patient with ALK+ ALCL and peripheral blood mononuclear cells from a patient with leukemic mantle cell lymphoma, both containing PD-L1-expressing tumor cells and tumor-associated T cells, were stimulated with phytohemagglutinin (a polyclonal T cell activator) and incubated with anti-PD-L1 antibody.

Levels of 16 inflammatory cytokines were measured as an assessment of T cell activity.

RESULTS: All 9 B cell lymphoma lines were negative for PD-L1, while all 5 ALCL cell lines were strongly positive.

One T-cell ALL line was positive, and one peripheral T cell lymphoma was negative.

Strong PD-L1 staining was detected by IHC in all 14 ALCL specimens and in 83% of diffuse large B cell lymphomas (DLBCL) analyzed (n=35).

Activity of allogeneic T cells co-cultured with irradiated ALCL cells, as measured by IFNγ secretion and proliferation, was markedly enhanced in the presence of anti-PD-L1 blocking antibody.

In the autologous setting using cultures of ALCL and mantle cell lymphoma specimens containing host T cells, secretion of inflammatory cytokines by tumor-associated T cells, including GMCSF, IFNγ, IL-1, IL-6, IL-8, TNFα, and MIP1α, were increased by incubation with anti-PD-L1 antibody.

Blockade of tumor-associated PD-L1 promoted activation of adjacent T cells.

PD-L1 may play a role in thwarting an effective anti-tumor immune response and represents an attractive target for lymphoma immunotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960901.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib.

: 8576 Deacetylases (DACs) are enzymes that remove the acetyl groups from target proteins [histones (class I) and non-histones (class II)], leading to regulation of gene transcription and other cellular processes.

LBH589 is a novel and potent DAC class I and II Inhibitor undergoing pre-clinical and clinical testing.

In order to develop therapeutic options for refractory/resistant B-cell lymphomas we studied the effects of LBH589 in the anti-tumor activity of chemotherapy agents and monoclonal antibodies in a panel of rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), and in lymphoma cells isolated from patients with treatment-naïve or refractory/relapsed B-cell lymphomas by negative selection using magnetic beads.

NHL cells lines were exposed to the following chemotherapy agents or monoclonal antibodies: CDDP, doxorubicin, vincristine, bortezomib or rituximab, veltuzumab, or isotype, alone or in combination with LBH589.

Patient-derived tumor cells were exposed to either LBH589, bortezomib or both.

Changes in ATP content were determined by cell titer glow assay.

RNA was isolated from NHL cell lines exposed to LBH859 and changes in gene expression of the Bcl-2 family members were determined by qualitative polymerase chain reaction (PCR).

LBH589 was active as a single agent against RSCL, RRCL or patient-derived tumor cells.

In addition, Bcl-XL gene down-regulation was observed following exposure to LBH859.

Our data suggests that LBH589 is active against various RSCL, RRCL and patient-derived tumor cells.

Findings suggest that LBH589 added to systemic anti-CD20 and/or chemotherapy could result in a novel and potent treatment strategy against B-cell lymphomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962275.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Results of autologous transplants for lymphomas from a tertiary cancer center in India.

: 7106 Background: Autologous stem cell transplanation is the standard of care for patients of relapsed and refractory non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL).

We report the results of transplants in lymphomas from our center and role of possible prognostic factors.

Seventy eight percent of patients received peripheral blood stem cells (PBSC), 8% bone marrow (BM) and 14% both PBSC and BM.

Prognostic factors evaluated for progression free survival (PFS) were serum albumin level and body mass index (BMI) at the time of transplant, stage at diagnosis and source of stem cells, while for over all survival (OS), status of disease at transplant was also included.

RESULTS: The median time to transplant was 2.25 years from the time of diagnosis.

At the time of transplant, thirty two percent were in complete remission (CR), 50% in partial remission (PR) and 18% had refractory disease (RD).

The best disease response rate was 86% (CR+PR) in patients evaluable for response.

CONCLUSIONS: These data provide the first published report of outcomes of autologous transplants in lymphomas from India.

Our data suggests that serum albumin level at the time of transplant and stem cell source are important prognostic factors for PFS and OS.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961648.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase I study of chidamide (CS055/HBI-8000), a novel histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.

: 3529 Background: Chidamide (CS055/HBI-8000) is a new benzamide type of histone deacetylase (HDAC) inhibitor with low nanomolar activity against HDAC1, 2, 3 and 10.

This Phase I study evaluated the safety and tolerability of chidamide in patients (pts) with advanced solid tumors and lymphomas.

METHODS: 31 pts with refractory or relapsed advanced solid tumors (22) and lymphomas (9) were enrolled in this study.

Significant induction of histone (H3) acetylation was observed in peripheral white blood cells, which lasted for 2-3 days in most pts after single dosing.

4 pts with T-cell lymphomas (4/5 evaluable) and 1 pt with submandibular adenoid cystic carcinoma achieved PR, and 11 pts (2 B-cell lymphomas and 9 solid tumors) experienced SD.

CONCLUSIONS: Chidamide was well-tolerated in pts with advanced solid tumors and lymphomas in the tested regimens.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961317.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Ongoing phase I studies of ABT-263: Mitigating Bcl-X_L induced thrombocytopenia with lead-in and continuous dosing.

: 3505 Background: ABT-263, a novel, oral BH3 mimetic, potently inhibits multiple antiapoptotic Bcl-2 family proteins.

Ongoing phase 1 studies of ABT-263 show anti-tumor activity in CLL and some lymphomas (Wilson W et al, ASH. 2008).

However, thrombocytopenia (TCP) due to on-target Bcl-X_L inhibition-induced platelet apoptosis is also observed.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961281.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization.

: 7040 Background: Patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) who fail to mobilize adequate peripheral blood stem cells (PBSC) often undergo bone marrow (BM) harvest for autologous transplantation.

Twelve pts (35%) had history of BM involvement with lymphoma.

At the time of stem cell mobilization 18 (50%) were in complete remission (CR), 13 (37%) were in partial remission (PR) and 5 (13%) had progressive disease (PD).

RESULTS: The median total nucleated cell dose and CD34+ cell dose harvested/kg were 3.72 x 10⁸ (range 0.25-58.0) and 1.6 x 10⁶ (range 0.03-5.8), respectively.

Causes of death were: disease progression/relapse in 15 (60%), secondary malignancy in 3 (12%), multiorgan failure in 5 (20%), and unknown in 2 (8%).

Non-myeloablative allogeneic transplantation may provide better outcomes with similar toxicity and needs to be further studied.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961403.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Low risk for symptomatic venous thromboembolic events (vte) during cytokine administration for peripheral blood stem cell mobilization.

METHODS: Between January 2000 and October 2008, a total of 631 patients underwent peripheral blood stem cell mobilization (PBSCM) using either GCSF, GMCSF, cyclophosphamide, AMD 3100, or with any of the above combination.

We included only patients with a diagnosis of AL amyloidosis (AL), multiple myeloma (MM) Hodgkin's lymphoma (HL) and non Hodgkin's lymphoma (NHL).

Patients' demographic details and diagnosis of VTE were collected from electronic medical records.

We found 7 (1.1%) patients with symptomatic VTE occurring between administration of growth factors and stem cell transplant.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961413.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High-dose intense doxorubicin-based regimens in aggressive non-Hodgkin's lymphoma: A systematic overview.

: e19528 Background: Aggressive non-Hodgkin's lymphoma represents around 60% of lymphomas in the Western world and even more in Egypt.

CHOP has been long been recognized as the standard chemotherapy regimen in this disease.

The addition of rituximab (R) to CHOP in the treatment of B-cell subtypes has resulted in a significant improvement in all treatment endpoints.

Thus CHOP is still offered to these patients as well as those with T-cell subtypes.

METHODS: A MEDLINE and COCHRANE library search was performed using the search terms 'CHOP', 'lymphoma' and 'randomized trials'.

Such approach should be considered in patients with aggressive B-cell lymphomas not offered R as well as those with T-cell lymphomas.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960914.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Analysis of prognostic factors in patients with EBV positive diffuse large B cell lymphoma of the elderly.

: e19542 Background: EBV positive diffuse large B cell lymphoma of the elderly is a new entity included in the Fourth edition of WHO Classification.

AIM: The goal of this study was to evaluate clinical characteristics and survival of EBV positive diffuse large B cell lymphoma of the elderly from Peruvian patients.

METHODS: Between January 2002 and June 2008, eleven patients with EBV positive diffuse large B cell lymphoma of the elderly were included in the analysis.

All cases were positive to the presence of EBV encoded RNA (EBER) by CISH and CD20 and/or Pax-5 expression by immunohistochemistry.Clinical data were reviewed retrospectively and patient's biopsies were analyzed for the immunohistochemical expression of BCL6, CD10, CD30 and MUM-1/IRF4 by tissue microarray (TMA) technique..

Extranodal disease occurred in 6/11 (54%) patients: pleura (n=2), suprarenal gland (n=1), stomach (n=1), cecum (n=1), bone (1), skin (1) and bone marrow (n=1).

Ten cases (83%) were of the Non-GC and 1 case was GC.

Complete response (n=2), partial response (n=0) and progressive disease (n=3).

CONCLUSIONS: EBV positive diffuse large B cell lymphoma of the elderly was related to high IPI, poor ECOG, frequent extranodal disease, poor response to treatment and very short survival.

It is the first report of this entity in a non-Asian population.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960995.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evaluation of the potential of histone deacetylase inhibitors to synergize the antineoplastic effects of the proteasome inhibitor bortezomib in mantle cell lymphoma (MCL).

HDACIs are known to induce cell death in malignant cells through multiple mechanisms, including up-regulation of death receptors, disruption of Hsp90 function and generation of reactive oxygen species.

Mantle cell lymphoma is an aggressive subtype of non-Hodgkin lymphoma characterized by the reciprocal translocation t(11;14)(q13;q32) leading to the overexpression of cyclin D1.

METHODS: We investigated the cytotoxicity of romidepsin and belinostat alone and in combination with the proteasome inhibitor bortezomib in cell lines of mantle cell lymphoma (HBL2, Granta519, Jeko1).

Cell Titer-Glo assay followed by luminometric acquisition was used for all cytotoxicity assays.

The combination of belinostat (100-1000nM) or romidepsin (1-40nM) with bortezomib (3-4nM) showed synergism in all cell lines at different concentrations.

Flowcytometry for apoptosis, cell cycle analysis and mitochondrial membrane potential as well as immunoblottings for hystone H3 acetylation, cyclin D1, Bcl-XL, Mcl-1, BIM and IKB-α suggest this strategy may modulate cyclin D1 and p27 in MCL which is known to be grossly deregulated for these proteins.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962269.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells.

Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies.

The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory disease.

Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

[MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / therapeutic use. Clinical Trials as Topic. Humans. Rituximab

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]

[Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]

[Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]

[Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]

[Cites] Ann Oncol. 2007 Jul;18(7):1216-23 [17470451.001]

[Cites] Clin Cancer Res. 2006 Jan 1;12(1):242-9 [16397048.001]

[Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]

[Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]

[Cites] Clin Cancer Res. 2004 Apr 15;10(8):2868-78 [15102696.001]

[Cites] Semin Immunol. 1998 Aug;10(4):287-97 [9695185.001]

[Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]

[Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]

[Cites] Cancer Res. 2005 Sep 15;65(18):8331-8 [16166310.001]

[Cites] Blood. 1984 Nov;64(5):1085-93 [6333257.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1926-30 [12571354.001]

[Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]

[Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]

[Cites] J Biol Chem. 2001 Mar 2;276(9):6591-604 [11096108.001]

[Cites] N Engl J Med. 1982 Mar 4;306(9):517-22 [6173751.001]

[Cites] Arthritis Res Ther. 2006;8(3):R74 [16630358.001]

[Cites] Drugs. 2007;67(3):333-50 [17335294.001]

[Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]

[Cites] Clin Cancer Res. 2004 Aug 15;10(16):5297-8 [15328164.001]

[Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]

[Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]

[Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]

[Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]

[Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]

[Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]

[Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]

[Cites] J Immunol. 2000 Apr 15;164(8):4178-84 [10754313.001]

[Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3995S-4002S [14506199.001]

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]

(PMID = 20425465.001).

[ISSN] 1558-822X

[Journal-full-title] Current hematologic malignancy reports

[ISO-abbreviation] Curr Hematol Malig Rep

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / PRO131921 monoclonal antibody; 0 / dacetuzumab; 0 / epratuzumab; 0 / ocrelizumab; 0 / veltuzumab; 357613-77-5 / galiximab; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab; M95KG522R0 / ofatumumab

[Number-of-references] 37

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Final results of NCCTG N0489: Epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma.

: 8508 Background: A prior pilot study of epratuzumab (Immunomedics) and rituximab in combination with CHOP chemotherapy (ER-CHOP) in untreated patients with diffuse large B-cell lymphoma demonstrated feasibility and safety.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960859.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Large B-cell non-Hodgkin lymphoma.

[MeSH-major] Lymphoma, Large B-Cell, Diffuse / diagnosis

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16315353.001).

[ISSN] 1523-6838

[Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation

[ISO-abbreviation] Am. J. Kidney Dis.

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies.

The PI3K p110δ isoform is highly expressed in cells of hematopoietic origin and plays a key role in B cell maturation and function.

In vitro studies of 0.1 to 10 μM CAL-101 showed inhibition of pAKT expression and/or apoptotic effects against primary chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) cells and against a range of leukemia and lymphoma cell lines.

METHODS: In an ongoing phase 1 dose escalation study in sequential cohorts of 3 patients with relapsed/refractory CLL or select B-cell non-Hodgkin's lymphoma, CAL-101 is administered orally twice daily for 28 days per cycle.

Clinical response is evaluated according to NCI criteria at the end of Cycles 1 and 2 and every 2 cycles thereafter.

Two of 6 patients attained partial response and 4 have stable disease.

Partial responses were observed after 2 cycles of 50 mg in a patient with mantle cell lymphoma with 6 prior therapies, and after 1 cycle of 100 mg in a patient with follicular lymphoma with 6 prior therapies, including autologous stem cell transplant.

Disease specific cohort expansion will occur at the maximally tolerated dose, and patients with AML will be added.

CONCLUSIONS: Early results from a phase 1 study of the oral PI3K p110δ inhibitor CAL-101 show that it is well tolerated and has preliminary clinical activity in patients with B-cell malignancies.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961357.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Our study was designed to evaluate the expression of p53, Bcl-2, Estrogen receptor (ER) and Progesterone receptor (PR) in ovarian carcinoma and to compare it with other prognostic parameters such as age, FIGO stage, size of residual tumor, histological type and grade.

We used immunohistochemistry to evaluate the expression of p53, Bcl-2, ER and PR receptors and Chi-Square and Student test to correlate immunohistochemical findings with some prognostic parameters of ovarian carcinoma.

Results: The percentage of expression of p53, Bcl-2, ER and PR was 73,7; 47,4; 35,1 and 33,3 % respectively. p53 overexpression correlated with an advanced FIGO stage (p = 0,026) and presence of ascitis (p < 10^-4).

The expression of PR was associated with an early stage (FIGO I and II), a non serous histologic type and a low tumour grade (p = 0,045; 0,010 and 0,036 respectively).

No correlation was found between Bcl-2 and ER and prognostic parameters.

Survival analysis revealed that Bcl-2 status, FIGO stage, presence of ascites, peritoneal cytology, and residual disease were significant predictive factors of survival.

Conclusion: p53 expression correlates with a worse prognosis in epithelial ovarian cancer, whereas Bcl-2 expression is related to a better outcome.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Gynecol Oncol. 1998 Jul;70(1):2-12 [9698465.001]

[Cites] Int J Gynecol Cancer. 2007 Mar-Apr;17(2):325-38 [17362310.001]

[Cites] Gynecol Oncol. 2005 Apr;97(1):46-52 [15790436.001]

[Cites] Lancet. 1997 Jan 11;349(9045):113-7 [8996432.001]

[Cites] Apoptosis. 1997;2(5):478-84 [14646531.001]

[Cites] Am J Clin Pathol. 1996 Mar;105(3):341-9 [8602616.001]

[Cites] Gynecol Oncol. 2005 Mar;96(3):671-7 [15721410.001]

[Cites] Gynecol Oncol. 1994 Jun;53(3):301-6 [8206402.001]

[Cites] Tunis Med. 2002 Feb;80(2):57-64 [12080555.001]

[Cites] Cancer Res. 1996 May 1;56(9):2178-84 [8616869.001]

[Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15(6):1014-22 [16343177.001]

[Cites] Obstet Gynecol. 1993 May;81(5 ( Pt 1)):643-50 [8469448.001]

[Cites] Int J Gynecol Cancer. 2004 Mar-Apr;14(2):259-70 [15086725.001]

[Cites] Cancer Gene Ther. 2002 Jul;9(7):553-66 [12082455.001]

[Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):720-7 [12445249.001]

[Cites] Cancer. 1990 Feb 1;65(3):486-91 [2297640.001]

[Cites] Cancer Chemother Pharmacol. 1999;44(2):143-51 [10412949.001]

[Cites] Br J Cancer. 2000 Dec;83(11):1488-94 [11076658.001]

[Cites] Br J Cancer. 1995 Nov;72(5):1324-9 [7577491.001]

[Cites] Cancer. 1995 Mar 15;75(6):1327-38 [7882283.001]

[Cites] Eur J Cancer. 1994;30A(11):1701-4 [7833147.001]

[Cites] J Endocrinol. 1998 Mar;156(3):503-8 [9582507.001]

[Cites] Cancer. 2000 Oct 15;89(8):1783-91 [11042574.001]

[Cites] Int J Gynecol Cancer. 2002 May-Jun;12(3):265-76 [12060448.001]

[Cites] Clin Biochem. 1999 Jul;32(5):333-8 [10480447.001]

[Cites] Am J Clin Oncol. 1998 Oct;21(5):447-51 [9781597.001]

[Cites] Mol Cancer Ther. 2004 Oct;3(10 ):1215-20 [15486188.001]

[Cites] Oncol Rep. 2007 Nov;18(5):1051-9 [17914554.001]

[Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]

[Cites] J Cancer Res Clin Oncol. 2001 Feb;127(2):73-9 [11216917.001]

[Cites] Eur J Cancer. 1998 May;34(6):845-50 [9797696.001]

[Cites] J Clin Oncol. 1994 Jan;12(1):64-9 [8270986.001]

[Cites] J Clin Oncol. 1999 Jul;17 (7):2061 [10561259.001]

[Cites] Cancer. 1997 Sep 1;80(5):892-8 [9307189.001]

[Cites] Acta Medica (Hradec Kralove). 2006;49(3):161-5 [17117604.001]

[Cites] J Huazhong Univ Sci Technolog Med Sci. 2004;24(2):151-3 [15315167.001]

[Cites] Eur J Cancer. 1999 Aug;35(8):1214-9 [10615232.001]

(PMID = 29147191.001).

[ISSN] 1920-454X

[Journal-full-title] World journal of oncology

[ISO-abbreviation] World J Oncol

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Keywords] NOTNLM ; Bcl-2 / Estrogen receptor / Ovarian carcinoma / Progesterone receptor / p53

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 2010 Background: R-(-)-gossypol (AT-101) is an oral bcl-2 family protein inhibitor (Bcl-2, Bcl-X_L, Mcl-1, Bcl-W) and potent inducer of proapoptotic proteins.

A prior study of racemic gossypol demonstrated objective responses in patients with malignant glioma.

METHODS: Fifty-six patients with recurrent GBM were enrolled in this multi-institution phase II clinical trial through the NABTT CNS consortium designed to detect a 33% increase in overall survival (OS, primary endpoint) from 5 to 6.65 months with Power/Alpha 80%/0.01.

Seven patients (16%) had stable disease as the best response.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27964593.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 2557 Background: AT-101 is an oral, pan-Bcl-2 inhibitor (Bcl-2, Bcl-XL, Bcl-W, Mcl-1).

Overexpression of Bcl-2 family proteins is common in human cancers.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961871.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Cutaneous B-cell non-Hodgkin lymphoma: clinical aspects, diagnostic and surgical approach].

[Transliterated title] Linfoma cutaneo non Hodgkin a immunofenotipo B: clinica, orientamento diagnostico e chirurgico.

By clinical observation and surgical treatment of a patient with cutaneous B-cell non-Hodgkin lymphoma, the Authors describe the nosological approach, the correct diagnosis and the surgical treatment in this disease.

[MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / surgery. Skin Neoplasms / diagnosis. Skin Neoplasms / surgery

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18544265.001).

[ISSN] 0391-9005

[Journal-full-title] Il Giornale di chirurgia

[ISO-abbreviation] G Chir

[Language] ita

[Publication-type] Case Reports; English Abstract; Journal Article

[Publication-country] Italy

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Coexistence of B-cell non-Hodgkin lymphoma and cutaneous T-cell lymphoma in a patient with chronic hepatitis C and cryoglobulinaemia.

The coexistence of chronic active hepatitis C with cryoglobulinemia and B-cell lymphoma has been presented in numerous case reports.

However, the combination of these conditions with T-cell lymphoma has never been described before.

We present the case of a patient who suffered chronic active hepatitis C, cryoglobulinaemia and B-cell lymphoma and was later complicated by cutaneous T-cell lymphoma (CTCL).

[MeSH-major] Cryoglobulinemia / complications. Hepatitis C, Chronic / complications. Lymphoma, B-Cell / complications. Lymphoma, T-Cell, Cutaneous / complications

[MeSH-minor] Adult. Bone Marrow Neoplasms / complications. Bone Marrow Neoplasms / virology. Female. Humans. Kidney Neoplasms / complications. Kidney Neoplasms / diagnosis. Kidney Neoplasms / virology. Liver Neoplasms / complications. Liver Neoplasms / virology. Skin Neoplasms / complications. Skin Neoplasms / virology

Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

Genetic Alliance. consumer health - Hepatitis.

Genetic Alliance. consumer health - Hodgkin lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19732202.001).

[ISSN] 1445-5994

[Journal-full-title] Internal medicine journal

[ISO-abbreviation] Intern Med J

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Australia

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] AIDS-related lymphoma (ARL): Efficacy of highly active anti retroviral therapy (HAART) on survival and prognostic factors in a general hospital in Peru.

METHODS: The clinical records of 2,502 HIV-infected patients seen in our institution from March 1997 to March 2008 were reviewed.

RESULTS: Forty-eight patients with HIV-associated lymphoma were identified.

From the 48 ARL identified 44 were non Hodgkin lymphoma (NHL) and 4 were Hodgkin lymphoma.

From 42 systemic NHL: 38 (90,5%) were of B-cell and 4 (9,5%) were of T-cell.

Three groups of patients were included: 13 patients (31%) received HAART previous the diagnosis of ARL, 21 patients (50%) initiated HAART after ARL diagnosis and 8 patients (19%) did not receive HAART.

HAART treatment before the diagnosis of NHL increases the survival (54% versus 9,5% versus 25% respectively, p=0.048).

In a multivariate analysis, IPI score > 2, presence of B symptoms and no HAART previous ARL diagnosis were statistically associated to worse survival with p-values of 0.0001, 0.018 and 0.048 respectively.

CONCLUSIONS: In our study the use of HAART is effective when started before ARL diagnosis.

IPI score > 2, B symptoms and no HAART previous the diagnosis were unfavorable prognostic factors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960996.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

The goal of this study was to evaluate the frequency of monoclonal serum FLC in patients with other B-cell malignancies.

Frozen sera from 226 patients with non-Hodgkin lymphoma (NHL) or chronic lymphocytic leukemia (CLL) were tested for M-protein by the serum FLC assay and compared with standard protein electrophoresis (PEL) and immunofixation (IF).

Within NHL, the highest incidences of FLC presence were in patients with mantle cell (36%) and small lymphocytic (24%).

Future studies are warranted to elucidate the role of serum FLC as biomarkers of disease, for monitoring of minimal residual disease, and as a prognostic factor for response and survival.

[MeSH-major] Immunoglobulin Light Chains / blood. Leukemia, Lymphocytic, Chronic, B-Cell / blood. Lymphoma, B-Cell / blood

Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Leukemia, B-cell, chronic.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17383597.001).

[ISSN] 1931-5244

[Journal-full-title] Translational research : the journal of laboratory and clinical medicine

[ISO-abbreviation] Transl Res

[Language] eng

[Grant] United States / NCI NIH HHS / CA / CA62242; United States / NCI NIH HHS / CA / CA97274

[Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin M

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Clinical impact and predisposing factors of delayed-onset neutropenia after autologous hematopoietic stem-cell transplantation for B-cell non-Hodgkin lymphoma: association with an incremental risk of infectious events.

BACKGROUND: Clinical significance of delayed-onset neutropenia (DON) after autologous hematopoietic stem-cell transplantation (ASCT) has not been well described.

We conducted a retrospective cohort study to examine risk factors and clinical impact of DON.

DESIGN AND METHODS: Subjects were consecutive 108 patients with B-cell lymphoma receiving ASCT.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Transplantation.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20172906.001).

[ISSN] 1569-8041

[Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology

[ISO-abbreviation] Ann. Oncol.

[Language] ENG

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma.

Elevated B-cell-activating factor (BAFF; TNFSF13B) levels have been found in patients with B-cell malignancies and autoimmune diseases, suggesting that it may play a pathogenic role.

We therefore wanted to determine if genetic variation in TNFSF13B is associated with high BAFF levels and non-Hogkin lymphoma (NHL) risk.

When categorized into low-, moderate-, and high-risk groups based on risk alleles, we found the permutation-corrected odds ratio for the trend to be 1.43 (P = 0.0019) for risk of B-cell NHL, 1.69 (P = 0.0093) for diffuse large B-cell lymphoma, 1.43 (P = 0.029) for follicular lymphoma, and 1.06 (P = 0.21) for chronic lymphocytic leukemia/small lymphocytic lymphoma.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Br J Haematol. 1997 Apr;97(1):107-12 [9136948.001]

[Cites] Arthritis Res Ther. 2006;8(1):R30 [16507129.001]

[Cites] Blood. 1998 May 15;91(10):3574-81 [9572991.001]

[Cites] Int Immunol. 1998 Nov;10(11):1693-702 [9846698.001]

[Cites] J Exp Med. 1999 Jun 7;189(11):1747-56 [10359578.001]

[Cites] Science. 1999 Jul 9;285(5425):260-3 [10398604.001]

[Cites] J Immunol. 2005 Jul 1;175(1):319-28 [15972664.001]

[Cites] Blood. 2005 Aug 1;106(3):1021-30 [15827134.001]

[Cites] J Exp Med. 1999 Dec 6;190(11):1697-710 [10587360.001]

[Cites] J Exp Med. 2000 Jul 3;192(1):129-35 [10880534.001]

[Cites] Mamm Genome. 2000 Aug;11(8):628-32 [10920230.001]

[Cites] Leuk Lymphoma. 2000 Aug;38(5-6):547-52 [10953976.001]

[Cites] Science. 2001 Sep 14;293(5537):2108-11 [11509692.001]

[Cites] J Clin Invest. 2002 Jan;109(1):59-68 [11781351.001]

[Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]

[Cites] Exp Hematol. 2002 Feb;30(2):135-41 [11823048.001]

[Cites] Blood. 2002 Oct 15;100(8):2973-9 [12351410.001]

[Cites] Blood. 2002 Oct 15;100(8):3037-40 [12351419.001]

[Cites] Genes Immun. 2002 Nov;3(7):424-9 [12424625.001]

[Cites] Nat Genet. 2003 Apr;33(4):439-40 [12665861.001]

[Cites] J Natl Cancer Inst. 2003 Apr 2;95(7):548-55 [12671023.001]

[Cites] J Biol Chem. 2003 Oct 3;278(40):38220-8 [12867412.001]

[Cites] Am J Hum Genet. 2004 Jan;74(1):106-20 [14681826.001]

[Cites] Blood. 2004 Jan 15;103(2):679-88 [14504101.001]

[Cites] Blood. 2004 Jan 15;103(2):689-94 [14512299.001]

[Cites] J Immunol. 2004 Jan 15;172(2):812-22 [14707051.001]

[Cites] J Immunol. 2004 Mar 1;172(5):3268-79 [14978135.001]

[Cites] Blood. 2004 Apr 15;103(8):3148-57 [15070697.001]

[Cites] Immunity. 2004 Apr;20(4):441-53 [15084273.001]

[Cites] Blood. 2004 May 1;103(9):3529-34 [14701701.001]

[Cites] Am J Hematol. 2004 May;76(1):14-8 [15114591.001]

[Cites] Blood. 2004 Oct 15;104(8):2247-53 [15251985.001]

[Cites] N Engl J Med. 1978 Nov 30;299(22):1215-20 [309554.001]

[Cites] Nat Genet. 2005 Aug;37(8):829-34 [16007086.001]

[Cites] Nat Genet. 2005 Aug;37(8):820-8 [16007087.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):3004-6 [16365026.001]

[Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D140-4 [16381832.001]

[Cites] Lancet Oncol. 2006 Jan;7(1):27-38 [16389181.001]

[Cites] J Clin Oncol. 2006 Feb 20;24(6):983-7 [16432079.001]

[Cites] Blood. 2006 May 15;107(10):4101-8 [16449530.001]

[Cites] Blood. 2006 Jun 1;107(11):4540-8 [16497967.001]

[Cites] Blood. 2007 Jan 15;109(2):729-39 [16960154.001]

[Cites] Br J Haematol. 2007 Jan;136(2):309-14 [17156395.001]

[Cites] Blood. 2007 Jun 15;109(12):5439-46 [17327408.001]

[Cites] Leuk Lymphoma. 2007 Sep;48(9):1869-71 [17786728.001]

[Cites] Blood. 2007 Dec 15;110(13):4455-63 [17827388.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3161-9 [18990758.001]

[Cites] Cancer. 1997 Oct 15;80(8):1489-96 [9338474.001]

(PMID = 19383901.001).

[ISSN] 1538-7445

[Journal-full-title] Cancer research

[ISO-abbreviation] Cancer Res.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA121569; United States / NCI NIH HHS / CA / R21 CA121569-02; United States / NCI NIH HHS / CA / CA121569-02; United States / NCI NIH HHS / CA / P50 CA097274-05; United States / NCI NIH HHS / CA / R01 CA092104; United States / NCI NIH HHS / CA / CA92153; United States / NCI NIH HHS / CA / CA092153-06; United States / NCI NIH HHS / CA / CA097274-05; United States / NCI NIH HHS / CA / R01 CA092153; United States / NCI NIH HHS / CA / CA097274; United States / NCI NIH HHS / CA / P50 CA097274; United States / NCI NIH HHS / CA / R01 CA092153-06; United States / NCI NIH HHS / CA / R21 CA121569

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / B-Cell Activating Factor; 0 / TNFSF13B protein, human

[Other-IDs] NLM/ NIHMS123245; NLM/ PMC2743448

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma.

BACKGROUND: Limited data exist about the role of second-line chemotherapy response assessed by positron emission tomography (PET) as a prognostic factor in patients with aggressive non-Hodgkin Lymphoma (NHL) who undergo autologous stem cell transplantation (ASCT).

The objective of this analysis was to investigate the main determinants of prognosis in patients with aggressive B-cell NHL who undergo ASCT, focusing on the impact of pretransplantation PET, secondary age-adjusted International Prognostic Index (sAA-IPI) score, histology, and previous response to first-line chemotherapy.

METHODS: Seventy-five patients with diffuse, large B-cell lymphoma or grade 3 follicular lymphoma who were treated at the author' institution with second-line chemotherapy (combined ifosfamide, etoposide, and epirubicin [IEV]) followed by ASCT between September 2002 and September 2006 were included.

CONCLUSIONS: The current data indicated that pretransplantation PET is the main prognostic predictor in patients with aggressive B-cell NHL who are scheduled for ASCT.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Lymphoma, Large B-Cell, Diffuse / therapy. Positron-Emission Tomography

[MeSH-minor] Adult. Aged. Carmustine / administration & dosage. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Fluorodeoxyglucose F18. Humans. Ifosfamide / administration & dosage. Lymphoma, Follicular / pathology. Lymphoma, Follicular / radionuclide imaging. Lymphoma, Follicular / therapy. Male. Melphalan / administration & dosage. Middle Aged. Predictive Value of Tests. Prognosis. Prospective Studies. Radiopharmaceuticals. Remission Induction. Salvage Therapy. Survival Analysis. Transplantation, Autologous. Vincristine / administration & dosage

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Transplantation.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. CYTARABINE .

Hazardous Substances Data Bank. MELPHALAN .

Hazardous Substances Data Bank. Carmustine .

Hazardous Substances Data Bank. ETOPOSIDE .

Hazardous Substances Data Bank. IFOSFAMIDE .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18833583.001).

[ISSN] 0008-543X

[Journal-full-title] Cancer

[ISO-abbreviation] Cancer

[Language] eng

[Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Radiopharmaceuticals; 04079A1RDZ / Cytarabine; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study.

We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma.

Twenty frail patients (median age, 73 years), as defined by Balducci et al., with diffuse large B cell or grade IIIb follicular lymphoma, either at diagnosis (15 patients) or relapsed (five patients), were prospectively enrolled.

With a median follow-up of 24 months (range 18-27), 15/18 responding patients (83%) are alive and disease free, as well as 3/18 are alive with active disease.

In conclusion, R-COMP-21 is an effective regimen with promising response rates for frail and elderly patients with aggressive non-Hodgkin lymphoma.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / drug therapy

[MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Frail Elderly. Humans. Lymphoma, Follicular / drug therapy. Male. Maximum Tolerated Dose. Middle Aged. Pilot Projects. Prednisone / administration & dosage. Prognosis. Prospective Studies. Rituximab. Treatment Outcome. Vincristine / administration & dosage

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DOXORUBICIN .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

Hazardous Substances Data Bank. VINCRISTINE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18569635.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Randomised comparison of two B-cell purging protocols for patients with B-cell non-Hodgkin lymphoma: in vivo purging with rituximab versus ex vivo purging with CliniMACS CD34 cell enrichment device.

We investigated the feasibility, safety and efficacy of two B-cell purging methods in patients with CD20+ non-Hodgkin lymphoma (NHL) receiving autologous stsem cell transplantation.

Twenty-seven patients were randomised to either in vivo purging with rituximab or ex vivo purging by CD34+ cell selection.

Both purging methods were efficient at eliminating B-cells in infusates.

When compared with in vivo purging, ex vivo purging was associated with CD34+ cell loss and delayed median neutrophil (10 d vs. 11 d) and platelet (12.5 d vs. 17 d) count recoveries.

In conclusion, although both purging methods were feasible and safe, rituximab purging was superior as it did not impair CD34+ cell mobilisation and was associated with faster myeloid recovery.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Bone Marrow Purging / methods. Lymphoma, B-Cell / therapy. Peripheral Blood Stem Cell Transplantation / methods

[MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antigens, CD34 / analysis. Feasibility Studies. Female. Hematopoietic Stem Cell Mobilization / methods. Humans. Immunomagnetic Separation / methods. Leukapheresis / methods. Male. Middle Aged. Rituximab

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. RITUXIMAB .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16371019.001).

[ISSN] 0007-1048

[Journal-full-title] British journal of haematology

[ISO-abbreviation] Br. J. Haematol.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P30CA43703

[Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD34; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.

PURPOSE: The growth of non-Hodgkin lymphomas can be influenced by tumor-immune system interactions.

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a negative regulator of T-cell activation that serves to dampen antitumor immune responses.

Blocking anti-CTLA-4 monoclonal antibodies improves host resistance to immunogenic tumors, and the anti-CTLA-4 antibody ipilimumab (MDX-010) has clinical activity against melanoma, prostate, and ovarian cancers.

EXPERIMENTAL DESIGN: We did a phase I trial of ipilimumab in patients with relapsed/refractory B-cell lymphoma to evaluate safety, immunologic activity, and potential clinical efficacy.

Two patients had clinical responses; one patient with diffuse large B-cell lymphoma had an ongoing complete response (>31 months), and one with follicular lymphoma had a partial response lasting 19 months.

In 5 of 16 cases tested (31%), T-cell proliferation to recall antigens was significantly increased (>2-fold) after ipilimumab therapy.

CONCLUSIONS: Blockade of CTLA-4 signaling with the use of ipilimumab is well tolerated at the doses used and has antitumor activity in patients with B-cell lymphoma.

Further evaluation of ipilimumab alone or in combination with other agents in B-cell lymphoma patients is therefore warranted.

[MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD / immunology. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):8099-103 [9223321.001]

[Cites] Immunity. 1997 Apr;6(4):411-7 [9133420.001]

[Cites] Blood. 1998 Aug 15;92(4):1184-90 [9694706.001]

[Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]

[Cites] Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11476-81 [10500201.001]

[Cites] Nat Med. 1999 Oct;5(10):1171-7 [10502821.001]

[Cites] Blood. 2005 Jan 1;105(1):13-21 [15353480.001]

[Cites] Curr Opin Oncol. 2005 Sep;17(5):432-40 [16093791.001]

[Cites] Blood. 2006 May 1;107(9):3639-46 [16403912.001]

[Cites] Clin Cancer Res. 2007 Feb 1;13(3):958-64 [17289891.001]

[Cites] Clin Cancer Res. 2007 Mar 15;13(6):1810-5 [17363537.001]

[Cites] Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10 [18287062.001]

[Cites] J Clin Oncol. 2008 Nov 10;26(32):5275-83 [18838703.001]

[Cites] J Clin Oncol. 2008 Dec 20;26(36):5950-6 [19018089.001]

[Cites] Blood. 2009 Feb 12;113(7):1581-8 [18974373.001]

[Cites] J Clin Oncol. 2009 Mar 1;27(7):1075-81 [19139427.001]

[Cites] Immunity. 1999 Oct;11(4):483-93 [10549630.001]

[Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]

[Cites] J Clin Oncol. 2001 Feb 1;19(3):720-6 [11157023.001]

[Cites] Immunity. 2001 Feb;14(2):145-55 [11239447.001]

[Cites] Annu Rev Immunol. 2001;19:565-94 [11244047.001]

[Cites] Blood. 2002 Mar 1;99(5):1517-26 [11861263.001]

[Cites] Eur J Immunol. 2002 Apr;32(4):972-81 [11920563.001]

[Cites] Int J Hematol. 2003 Jun;77(5):444-55 [12841382.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8372-7 [12826605.001]

[Cites] Cancer. 1980 Nov 1;46(9):2093-9 [7427915.001]

[Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]

[Cites] N Engl J Med. 1992 Oct 22;327(17):1209-15 [1406793.001]

[Cites] Immunity. 1994 Aug;1(5):405-13 [7882171.001]

[Cites] J Exp Med. 1995 Aug 1;182(2):459-65 [7543139.001]

[Cites] Science. 1996 Mar 22;271(5256):1734-6 [8596936.001]

[Cites] Annu Rev Immunol. 1996;14:233-58 [8717514.001]

[Cites] Immunol Rev. 1996 Oct;153:27-46 [9010718.001]

[Cites] Blood. 1997 May 1;89(9):3129-35 [9129015.001]

[Cites] Cancer Res. 1997 Sep 15;57(18):4036-41 [9307290.001]

(PMID = 19808874.001).

[ISSN] 1078-0432

[Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research

[ISO-abbreviation] Clin. Cancer Res.

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R21 CA108182-02; United States / NCI NIH HHS / CA / U01 CA069912; United States / NCI NIH HHS / CA / U01 CA069912-15; United States / NCI NIH HHS / CA / R21 CA108182; United States / NCI NIH HHS / CA / U01 CA69912

[Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antineoplastic Agents; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 6T8C155666 / ipilimumab

[Other-IDs] NLM/ NIHMS140341; NLM/ PMC2763019

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bcl-2 family members: Dual regulators of apoptosis and autophagy.

In normal conditions, Beclin 1 is bound to and inhibited by Bcl-2 or the Bcl-2 homolog Bcl-X_L.

This interaction involves a Bcl-2 homology 3 (BH3) domain in Beclin 1 and the BH3 binding groove of Bcl-2/Bcl-X_L.

Other proteins containing BH3 domains, called BH3-only proteins, can competitively disrupt the interaction between Beclin 1 and Bcl-2/Bcl-X_L to induce autophagy.

Nutrient starvation, which is a potent physiologic inducer of autophagy, can stimulate the dissociation of Beclin 1 from its inhibitors, either by activating BH3-only proteins (such as Bad) or by posttranslational modifications of Bcl-2 (such as phosphorylation) that may reduce its affinity for Beclin 1 and BH3-only proteins.

Thus, anti-apoptotic Bcl-2 family members and pro-apoptotic BH3-only proteins may participate in the inhibition and induction of autophagy, respectively.

This hitherto neglected crosstalk between the core machineries regulating autophagy and apoptosis may redefine the role of Bcl-2 family proteins in oncogenesis and tumor progression.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 28186856.001).

[ISSN] 1554-8635

[Journal-full-title] Autophagy

[ISO-abbreviation] Autophagy

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Bortezomib, bendamustine, and rituximab in patients (pts) with relapsed (rel) or refractory (ref) follicular lymphoma (FL): Dose-finding results of the VERTICAL study.

: 8550 Background: FL is an incurable indolent B-cell non-Hodgkin's lymphoma.

Bortezomib (Velcade, V) plus R was active and generally well tolerated in rel/ref FL [de Vos ASH 2006 Abs694], and bendamustine hydrochloride (Treanda, B) plus R has also shown activity in heavily pretreated FL [Robinson JCO 2008].

METHODS: Pts with relapsed FL with ≥4 prior doses of R (no prior V or B), ≥1 measurable tumor mass, no active central nervous system lymphoma, KPS ≥50%, adequate hematologic, renal and hepatic function, and no peripheral neuropathy ≥G2 were eligible.

B dose escalation continued based on cycle 1 dose-limiting toxicities (DLTs), defined as: treatment-related platelet count <25,000/mm³ for >7 days or any platelet count <10,000/mm³; G4 neutropenia for >7 days; any treatment-related ≥G3 non-hematologic toxicity other than inadequately treated nausea, vomiting, or diarrhea; or any toxicity resulting in >1 week treatment delay.

RESULTS: Sixteen pts (4 at B 50 mg/m², 6 each at B 70 and 90 mg/m²) with a median of 3 prior therapies (range 1-13; 31% prior stem-cell transplantation) have been treated (15 evaluable for DLT); median age was 54.5 (44-80) yrs.

Non-hematologic AEs ≥G3 in >1 pt were diarrhea (31%), fatigue (25%), vomiting (13%), and nausea (13%).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960956.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Association of primary mediastinal B-cell lymphoma (PMBL) in children (C) and adolescents (A) with a significantly inferior prognosis: Final results of the FAB/LMB 96 trial.

: 10001 Background: Single pediatric cooperative group studies have demonstrated an EFS ranging from 65 - 75% in C & A with large cell lymphomas arising in the mediastinum (Lones/Cairo et al, J Clin Oncol, 2000; Burkhardt/Reiter et al, Br J Haematol, 2005; Seidman/Reiter et al, J Clin Oncol, 2003).

Recently, Staudt and Shipp have independently demonstrated that following gene expression profiling by oligonucleotide microarray that PMBL resembles more like classical Hodgkin lymphoma than diffuse large B-cell lymphoma with enhanced NF-κB pathway gene expression (Rosenwald et al, J Exp Med, 2003; Abramson et al, Blood, 2005).

RESULTS: There were 528 patients with stage III/IV disease treated on group B therapy on FAB/LMB 96 resulting in a 2 yr EFS of 84% (CI₉₅: 82-86%).

5 yr EFS was significantly inferior compared to the remainder of the other patients with stage III disease treated on group B therapy (54%: CI₉₅ 38-68% vs 85%: CI₉₅ 81-88%) (p < 0.001).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962546.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognostic significance of vascular endothelial growth factor (VEGF), VEGF receptors (VEGFR), and vascularity in diffuse large B-cell lymphoma treated with immunochemotherapy (R-CHOP).

: 8581 Background: Diffuse large B cell lymphoma (DLBCL) cells coexpress VEGF, VEGFR1 and VEGFR2.

METHODS: 162 pts with de novo DLBCL treated with R-CHOP and median followup of 44 months were evaluated retrospectively with immunohistochemistry on tissue microarrays.

Scoring: VEGF, VEGFR1, VEGFR2, and phosphoVEGFR2 (pVEGFR2) in lymphoma cells (categorical variable) <5%, none; 5-30%, weak; >30%, strong.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962266.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] The prognostic significance of the number of extranodal sites in the patients with disseminated diffuse large B-cell lymphoma treated with R-CHOP.

: 8570 Background: The combination of rituximab and CHOP chemotherapy (R-CHOP) has improved survival of patients with diffuse large B-cell lymphoma (DLBCL).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961016.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by autologous stem cell transplantation: CORAL study.

: 8509 Background: Salvage chemotherapy followed by high dose therapy and autologous stem cell transplantation (ASCT) is the standard of treatment for chemosensitive relapses in diffuse large B cell lymphoma.

Patients with prior exposure to rituximab had more refractory disease and adverse prognostic factors.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960863.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] A phase II trial of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for patients with refractory or relapsed non-Hodgkin's lymphoma.

: 8559 Background: Gemcitabine combined with cisplatin has been known as an effective regimen for lymphoma treatment in salvage setting.

We investigated the response rate and toxicity of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOx) for recurrent or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), looking for the more effective and less toxic therapy.

METHODS: Patients with recurrent or refractory diffuse large B-cell NHL or mantle cell lymphoma, measurable disease, and more than one previous chemotherapy regimen were eligible.

Patients could then proceed to stem cell transplantation (SCT) or receive up to six treatment cycles.

The median age of the patients was 54 years (range, 18-75 years) and most had diffuse large-cell lymphoma.

CONCLUSIONS: GIDOx is an active salvage regimen in aggressive B-cell NHL and can be administered with acceptable toxicity.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960992.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis.

Lymphomas are classified according to the World Health Organisation (WHO) classification which defines subtypes on the basis of clinical, morphological, immunophenotypic, molecular and cytogenetic criteria.

Differential diagnosis of the subtypes is sometimes difficult, especially for small B-cell lymphoma (SBCL).

Standardisation of molecular genetic assays using multiple gene expression analysis by microarrays could be a useful complement to the current diagnosis.

The aim of the present study was to develop a low density DNA microarray for the analysis of 107 genes associated with B-cell non-Hodgkin lymphoma and to evaluate its performance in the diagnosis of SBCL.

A predictive tool based on Fisher discriminant analysis using a training set of 40 patients including four different subtypes (follicular lymphoma n = 15, mantle cell lymphoma n = 7, B-cell chronic lymphocytic leukemia n = 6 and splenic marginal zone lymphoma n = 12) was designed.

This pilot study demonstrates that such a microarray tool may be a promising diagnostic approach for small B-cell non-Hodgkin lymphoma.

[MeSH-major] Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Lymphoma, B-Cell / diagnosis. Oligonucleotide Array Sequence Analysis

[MeSH-minor] Artificial Intelligence. Diagnosis, Differential. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphoma, B-Cell, Marginal Zone / diagnosis. Lymphoma, B-Cell, Marginal Zone / genetics. Lymphoma, Follicular / diagnosis. Lymphoma, Follicular / genetics. Lymphoma, Mantle-Cell / diagnosis. Lymphoma, Mantle-Cell / genetics. Pilot Projects. RNA, Neoplasm / analysis. RNA, Neoplasm / isolation & purification

Genetic Alliance. consumer health - Hodgkin lymphoma.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19294557.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / RNA, Neoplasm

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] bcl-2 expression and possibility of bladder preservation using combined modality treatment in muscle-invasive transtional cell carcinoma.

To evaluate the combined modality treatment and selective bladder preservation and to evaluate BCL-2 expression that may predict treatment response and survival.

METHODS: 66 eligible patients with T2-4a NxM0 transitional cell carcinoma received two courses of gemcitabine and cisplatin followed by 45 Gy of pelvic radiotherapy in 1.8 Gy fractions with concomitant cisplatin.

Immunohistochemistry was used to assess the tumor cell expression of BCL-2.

Bcl-2 was expressed in 35 (53%) of the patients.

Bcl-2 immunoreactivity was inversely correlated with of histological grade (p = 0.0232) and was not correlated with gender distribution (p = 0.4666), the clinical stage (T) (p = 0.4325) or response to treatment (p = 0.6234).

No significant difference was noted between the cause-specific survival rate of patients with positive Bcl-2 expression and those with negative BCL-2 expression.

CONCLUSIONS: this combined approach of chemotherapy and radiation therapy with bladder preservation should be considered as an option for muscle-invasive transitional cell carcinoma of bladder.

Assessment of Bcl-2 protein expression may be used to predict a clinical response to this combined modality approach.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963367.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIF expression and Max-SUV-18F-FDG-PET in non-small cell lung cancer (NSCLC) patients.

WI) to construct a TMA block, according to conventional protocols for the study of immunohistochemical expression of HIF-1α, HIF-2 α, EGFR, bcl-2, MIB1, p16, p63 and cyclins A, B1, D1 and D3.

Sections were scored as positive if >10% of cells stained positively.

Staining patterns were correlated to clinical variables.

RESULTS: HIF- 1α expression was observed in 84/96 patients (34/39 adenocarcinomas and 50/57 squamous cell carcinomas), however it did not correlate with clinical stage (I-II: 41/45 vs III-IV: 44/51).

HIF-2 α expression was observed in 60/103 cases (27/42 adenocarcinomas and 33/61 squamous cell carcinomas) and it did not correlate with clinical stage ((I-II: 28/45 vs III-IV: 32/57).

After multivariate analysis, only the clinical stage (RR: 2,2) was a prognostic factor. CONCLUSIONS:.

1) HIF-1α and HIF-2 α expressions are frequent in patients with NSCLCs and it did not correlate with clinical stage;.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27963184.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Outcome and molecular features of head and neck squamous cell carcinomas (HNSCC) bearing a p16 high phenotype.

: 6031 Background: We have previously demonstrated that p16 expression defines a biologically distinct subgroup of oropharyngeal squamous cell cancers (OSCC).

Protein expression levels for a panel of 13 markers (EGFR, MET, STAT 3, ERK 1/2, pAkt, PI3Kp85, PI3Kp110, PTEN, p53, Bcl-2, E-cadherin, β-catenin, NFκB) were analyzed using AQUA.

p16 positive tumors also expressed higher levels of PTEN (p = 0.0009), PI3Kp110 (p = 0.03), NFκB (p = 0.007), and Bcl-2 (p = 0.005).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962428.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

: 3577 Background: AT-101 inhibits the Bcl-2 protein family (Bcl-2, Bcl-xL, Mcl-1, Bcl-W) with broad preclinical activity including synergy with D.

A biomarker of AT-101 activity was developed by treating 55 NSCLC cell lines with AT-101 and using the corresponding gene expression data to identify a genomic predictor of sensitivity to AT-101.

Analysis of gene expression data by Bayesian regression revealed a robust 500 gene predictor of sensitivity to AT-101 that was cross validated in a leave one out analysis and in an independent cohort of 32 NSCLC cell lines.

CONCLUSIONS: In this phase II trial AT-101, an oral pan Bcl-2 family inhibitor, had favorable OS compared to placebo when combined with docetaxel in previously treated NSCLC and was well tolerated.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961708.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] [Hepatitis B reactivation in an HbsAg-negative/anti-HBc-positive patient with B-cell non-Hodgkin lymphoma receiving chemotherapy with rituximab].

[Transliterated title] Reactivación de la hepatitis B en un paciente HBsAg negativo/antiHBc positivo con linfoma B que recibió quimioterapia con rituximab.

We present the case of a patient with B-cell non-Hodgkin lymphoma receiving combination chemotherapy with rituximab who showed hepatitis B reactivation followed by liver failure.

[MeSH-major] Antibodies, Monoclonal / adverse effects. Hepatitis B Antibodies / blood. Hepatitis B Core Antigens / immunology. Hepatitis B virus / physiology. Hepatitis B, Chronic / complications. Immunologic Factors / adverse effects. Immunotherapy / adverse effects. Lymphoma, B-Cell, Marginal Zone / complications. Virus Activation / drug effects. Virus Activation / immunology

Genetic Alliance. consumer health - Hepatitis.

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

Hazardous Substances Data Bank. PREDNISONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20363054.001).

[ISSN] 0210-5705

[Journal-full-title] Gastroenterología y hepatología

[ISO-abbreviation] Gastroenterol Hepatol

[Language] spa

[Publication-type] Case Reports; English Abstract; Journal Article; Review

[Publication-country] Spain

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Hepatitis B Antibodies; 0 / Hepatitis B Core Antigens; 0 / Hepatitis B Surface Antigens; 0 / Immunologic Factors; 0 / Organophosphonates; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 99YXE507IL / Tenofovir; JAC85A2161 / Adenine; VB0R961HZT / Prednisone; COP protocol 2

[Number-of-references] 33

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.

[MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / drug effects. Lymphoma, Large B-Cell, Diffuse / drug therapy. Neoplasm Recurrence, Local / drug therapy. Salvage Therapy

Genetic Alliance. consumer health - Hodgkin lymphoma.

Genetic Alliance. consumer health - Large B cell diffuse lymphoma.

Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

Hazardous Substances Data Bank. RITUXIMAB .

Hazardous Substances Data Bank. DEXAMETHASONE .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20629527.001).

[ISSN] 1029-2403

[Journal-full-title] Leukemia & lymphoma

[ISO-abbreviation] Leuk. Lymphoma

[Language] eng

[Publication-type] Letter

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Rituximab in the treatment of B-cell non-Hodgkin lymphoma, focus on outcomes and comparative effectiveness.

Rituximab is an important and well established component in the treatment of many patients with B-cell non-Hodgkin lymphoma.

In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of patients with diffuse large B cell lymphoma and follicular lymphoma.

More uniquely, we review economic aspects of lymphoma treatments, including the cost of standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in both induction and maintenance treatment, and lymphoma's impacts on patient's productivity and their caregivers.

We conclude that adding rituximab to standard chemotherapy treatment for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings during both induction and maintenance therapies.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Clin Oncol. 2006 Jul 1;24(19):3121-7 [16754935.001]

[Cites] Eur J Cancer. 2001 Sep;37(14):1781-9 [11549432.001]

[Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]

[Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]

[Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]

[Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]

[Cites] Semin Oncol. 2002 Feb;29(1 Suppl 2):2-9 [11842383.001]

[Cites] Blood. 2004 Feb 1;103(3):777-83 [12907446.001]

[Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]

[Cites] N Engl J Med. 2005 Feb 3;352(5):441-9 [15689582.001]

[Cites] Eur J Haematol. 2005 Mar;74(3):194-202 [15693788.001]

[Cites] Cancer. 2005 Mar 15;103(6):1292-301 [15700265.001]

[Cites] Cancer. 2005 Apr 15;103(8):1644-51 [15756658.001]

[Cites] J Clin Oncol. 2005 Apr 1;23(10):2240-7 [15800314.001]

[Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]

[Cites] Blood. 2006 Jan 1;107(1):265-76 [16150940.001]

[Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]

[Cites] Ann Oncol. 2006 May;17 Suppl 4:iv25-30 [16702181.001]

[Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]

[Cites] Br J Haematol. 2003 Apr;121(1):44-8 [12670330.001]

[Cites] Blood. 2004 May 15;103(10):3684-8 [14739217.001]

[Cites] Blood. 2004 Jun 15;103(12):4416-23 [14976046.001]

[Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]

[Cites] Haematologica. 2005 May;90(5):661-71 [15921381.001]

[Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]

[Cites] Value Health. 2005 Jul-Aug;8(4):462-70 [16091023.001]

[Cites] Ann Hematol. 2006 Aug;85(8):530-4 [16639571.001]

[Cites] Lancet Oncol. 2008 Feb;9(2):105-16 [18226581.001]

[Cites] Leuk Lymphoma. 2008 Feb;49(2):227-36 [18231908.001]

[Cites] Value Health. 2008 Mar-Apr;11(2):221-30 [18380634.001]

[Cites] Acta Oncol. 2008;47(6):1029-36 [18607857.001]

[Cites] Clin Lymphoma Myeloma. 2008 Jun;8(3):166-70 [18650180.001]

[Cites] Bone Marrow Transplant. 2009 May;43(9):701-8 [19029963.001]

[Cites] J Clin Oncol. 2009 Apr 1;27(10):1607-14 [19255334.001]

[Cites] Cochrane Database Syst Rev. 2009;(2):CD006552 [19370640.001]

[Cites] Blood. 2006 Nov 15;108(10):3295-301 [16873669.001]

[Cites] Cochrane Database Syst Rev. 2008;(1):CD004024 [18254036.001]

[Cites] J Clin Oncol. 2008 Sep 20;26(27):4473-9 [18626004.001]

[Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]

[Cites] Ann Hematol. 2009 Jan;88(1):51-7 [18665360.001]

[Cites] J Clin Oncol. 2008 Nov 10;26(32):5156-64 [18854568.001]

[Cites] Psychooncology. 2009 May;18(5):554-9 [18942670.001]

[Cites] J Clin Oncol. 2009 Mar 10;27(8):1202-8 [19204203.001]

[Cites] Bone Marrow Transplant. 1997 Nov;20(10):889-96 [9404932.001]

(PMID = 21935313.001).

[ISSN] 1178-6981

[Journal-full-title] ClinicoEconomics and outcomes research : CEOR

[ISO-abbreviation] Clinicoecon Outcomes Res

[Language] eng

[Publication-type] Journal Article

[Publication-country] New Zealand

[Other-IDs] NLM/ PMC3169958

[Keywords] NOTNLM ; cost effectiveness / lymphoma / rituximab / safety / transplant

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Moreover we investigated whether p53, Ki67, bcl-2, c-erbB-2 protein expression predict the achievement of a complete response (CR).

At the response evaluation, pts with biopsy proven residual disease were considered incomplete responders (IR) and underwent immediate cystectomy.

Paraffin embedded blocks of the primary tumors were collected and Ki67, p53, bcl-2 and c-erbB-2 protein expression were evaluated in a blind fashion.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962925.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effect of mebendazole on melanoma xenograft growth through targeting of bcl-2.

: 9075 Background: Defects in apoptosis are thought to contribute to melanoma chemoresistance, making the anti-apoptotic protein Bcl-2 an attractive therapeutic target.

We identified mebendazole (MBZ), a microtubule binding agent, as an inducer of melanoma cytotoxicity via a Bcl-2 dependent mechanism in vitro (Mol Cancer Res, Aug 2008).

In the present study, we assessed the effect of MBZ on human melanoma tumor growth and progression in a mouse xenograft model and compared the ability of MBZ to inhibit growth of cultured melanoma cells to that of oblimersen (OBL), an antisense drug targeting Bcl-2.

Bcl-2 phosphorylation was determined by immunoblotting.

This reduction in volume was accompanied by a 46% decrease in proliferating cells and an 81% increase in apoptotic cells.

Orally administered MBZ treatment resulted in Bcl-2 phosphorylation in vivo, further confirming its mechanism of action.

MBZ inhibited growth of melanoma cells in culture more effectively than OBL with GI50 values of 0.32 uM and 7.45 uM, respectively.

A phase II clinical trial investigating MBZ's utility as adjuvant therapy in patients with stage IV, resected melanoma is planned.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27962178.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effects of FCGR3A and FCGR2A polymorphisms on outcomes of patients with diffuse large B-cell lymphoma treated with CHOP-like chemotherapy versus CHOP-rituximab.

: 8567 Background: The addition of rituximab to cyclophosphamide/ doxorubicin/ vincristine/ prednisone (R-CHOP) therapy for diffuse large B-cell lymphoma (DLBCL) has significantly improved the outcome for many patients (pts).

In a multivariate analysis for risk of progression or death: FCGR2A : H/H vs. H/R or R/R by treatment type: CHOP-like [RR 0.63 (95% CI 0.37-1.08), p=0.10] and R-CHOP [RR 0.59 (0.36-0.96), p=0.04] and for FCGR3A V/V vs. F/V or F/F by treatment arm: CHOP-like [RR 0.75 (0.36-1.54), p=0.43] and R-CHOP [RR 2.28(0.70-7.44), p=0.17].

However, our study also suggests that a trend toward association of certain polymorphisms with clinical outcomes.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27961024.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Neutrophil toxicity and primary prophylaxis in diffuse large B cell lymphoma treated with R-CHOP.

: e19548 Background: Three weekly R-CHOP therapy is regarded as standard treatment in advanced stage Diffuse Large B Cell Lymphoma (DLBCL) patients with low to intermediate-risk International prognostic index (IPI).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960978.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Long term follow-up of primary B and T cell non-Hodgkin's lymphoma (NHL) of the gastrointestinal (GI) tract.

: e19516 Background: Anthracycline based chemotherapy is the treatment of choice for aggressive primary lymphomas of the GI tract, with surgery reserved for management of complications.

Median age at diagnosis was 60 (15-83).

52 (73%) were DLBCL, 11 (16%) were T-cell, 8 (11%) were MALT.

Of the aggressive lymphomas (63), all patients with T cell lymphoma had small bowel as primary site and histological evidence of celiac associated enteropathy, even in the absence of known celiac disease.

39 (62%) patients underwent surgery at diagnosis due to acute presentation with perforation, bleeding or obstruction, or to obtain histology.

Following confirmed diagnosis, 61 patients received anthracycline based chemotherapy.

2 patients with T cell lymphoma presented with perforation, were treated with surgery only and died of rapid disease progression.

Of the 63 patients with aggressive NHL, 37 (59%) remain alive & disease free at median follow up of 13 years (1-24).

35 (67%) patients with DLBCL are alive & disease free.

Only 2 (18%) of the T cell lymphomas are alive & disease free.

All deaths in the T cell group were due to progressive disease.

CONCLUSIONS: Patients with aggressive primary B cell GI NHL have almost 70 % survival following anthracycline based chemotherapy.

However, in contrast, coeliac enteropathy associated T-cell lymphomas present with rapidly progressive disease & have a survival of < 20% with chemotherapy and/or surgery.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 27960953.001).

[ISSN] 1527-7755

[Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology

[ISO-abbreviation] J. Clin. Oncol.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States